50.6 F
New York
Friday, December 4, 2020

Kazia Therapeutics’ [NASDAQ: KZIA] Paxalisib Receives Orphan Drug Designation

Must read

Ring [NYSEMKT: REI] Energy Started Drilling Operation In New Horizontal Well

Ring Energy declared that the company has started operations on its new well. The company told that in ten months, it finally initiated...

KKR [NYSE: KKR] Purchased Two Industrial Properties Of Worth $171Million

KKR & Co. Inc. announced that it purchased two properties in texas for distribution purposes. The industrial properties total an area of...

EchoStar [NASDAQ: SATS] Partners With JT And Brings A Single Terminal For Network Connectivity To Market

EchoStar Corp.  declared that it has collaborated with Jersey Telecom so that it can provide its clients in the United Kingdom and Europe...

Capstone [NASDAQ: CPST] Receives An 800Kw Microturbine Order From Costa

Capstone Turbine Corp. declared that it has acquired an order of 800KW microturbine from the Costa Group. The request was obtained by the...

Kazia Therapeutics [NASDAQ: KZIA] disclosed Monday that its Paxalisib has got the orphan drug designation from the US FDA. Paxalisib is formerly known as GDC-0084 for the treatment of malignant glioma.

Orphan Drug Designation is the special status awarded to the drugs which has the potential to treat rare diseases. The one benefit of ODD is that it provide the Orphan Drug Exclusivity to drug developers.

Another benefit is that it gives opportunities for grant funding, protocol assitance, and finacial benefits includes waiver of New Drug Application fees, and tax credits.

Shares of Kazia Therapeutics soared 2.47% at $7.48 during the trading of Friday. It has day low and high range of $6.86-$7.59, respectively.

In the past 52-weeks of trading, this company’s stocks fluctuated between the low of $2.27 and a high of $9.74. It has moved up 230.11% from its 52-weeks low and moved down -23.20% from its 52-weeks high.

Kazia Therapeutics has a trading volume of 797.73K and an average volume of 566.62K. Looking at its liquidity, its current ratio is 2.40. Similarly, its quick ratio is also 2.40. Furthermore, its market capitalization is 76.07 million.

Kazia disclosed that it will present its data from its ongoing phase II study of paxalisib in glioblastoma at the Society for Neuro-Oncology (SNO) Annual Meeting in November 2020.

More articles

Latest article

Vodafone [NASDAQ: VOD] and RingCentral signs a partnership to provide next-generation services

Vodafone signed a strategic alliance with Ring Central . The association will modify business connections and alliances. The enterprises have joined hands to...

Salesforce [NYSE: CRM] Enters A Deal To Acquire Slack

Salesforce engages in a contract to buy Slack at a worth of $27.7B. This purchase to build an operating system for the...

Xilinx [NASDAQ: XLNX] Announced That It Acquired Falcon Computing

Xilinx Inc. declared that it has purchased falcon Computing Solutions to make flexible computing more accessible and easily adapted by computer programmers. The...

Luokung Corp. [NASDAQ: LKCO] To Acquire EMG For RMB 836 Million

Luokung Technologies Corp. a location-based service company has agreed to buy EMG technologies for Ren Min Bi  836 million. The company will pay...

Nokia [NYSE: NOK] Extends Collaboration With AT&T to Deliver Seamless IoT Connectivity

Nokia Corp. declared that the company has extended its contract with AT&T . The collaboration among the companies can supply and provide an...

Wendy [NASDAQ: WEN] Strikes A Deal With Rebel Foods To Open 250 Cloud Kitchens.

Wendy’s Co. and Rebel foods have partnered to open about 250 cloud kitchens in India. These kitchens will only serve the customer with...

Tesla [NASDAQ: TSLA] Recalls 9537 SUV’s Because Of Manufacturing Issues

Tesla Inc. has released safety recall orders for more than 9500 of its vehicle in the United States. The vehicles include Model Xs...

Northrop [NYSE:NOC] awarded a deal of $4.8B for Global Hawk Aircraft

Northrop Gruman Corp. has been awarded a deal to perform development, transformation, retrofit, and sustenance activities for the Global Hawk Program. This deal...